XOI — Competitive Intelligence Brief

XOI (XOI) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Guanylate cyclase-C agonist. Area: Gastroenterology.

marketed Guanylate cyclase-C agonist GC-C (guanylate cyclase-C) Gastroenterology Small molecule

Target snapshot

XOI (XOI) — Ironwood Pharmaceuticals, Inc.. XOI is a guanylate cyclase-C (GC-C) agonist that increases intracellular cGMP in intestinal epithelial cells to promote fluid secretion and bowel motility.

Comparator set (4 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
XOI TARGET	XOI	Ironwood Pharmaceuticals, Inc.	marketed	Guanylate cyclase-C agonist	GC-C (guanylate cyclase-C)
Trulance	PLECANATIDE	Salix	marketed	Guanylate Cyclase-C Agonist [EPC]	Tumor necrosis factor	2017-01-01
Linzess	LINACLOTIDE	AbbVie	marketed	Guanylate Cyclase-C Agonist [EPC]	Heat-stable enterotoxin receptor	2012-01-01
Linaclotide 72 micrograms	Linaclotide 72 micrograms	Md Mehedi Shahriar	marketed	Guanylate cyclase-C agonist	GC-C (guanylate cyclase-C receptor)
AJG555	AJG555	EA Pharma Co., Ltd.	phase 3	Guanylate cyclase-C agonist	GC-C (guanylate cyclase-C)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Guanylate cyclase-C agonist class)

1. EA Pharma Co., Ltd. · 1 drug in this class
2. Ironwood Pharmaceuticals, Inc. · 1 drug in this class
3. Md Mehedi Shahriar · 1 drug in this class